Skip to content.

IMV completes registered direct offering for proceeds of approximately US$9M

Date Closed

December 20, 2022

Lead Office

Québec City


9.00 Million USD

On December 20, 2022, IMV Inc. closed its previously announced registered direct offering for total gross proceed of approximately US$9M. 

IMV intends to use the net proceeds from the offering to continue the clinical development of its lead product candidate, maveropepimut-S, in diffuse large B cell lymphoma (DLBCL), ovarian cancer, the completion of its ongoing basket trial and to continue the development of its proprietary drug delivery platform (DPX®) and for general corporate purposes. 

IMV Inc. is a clinical-stage immuno-oncology company advancing a portfolio of therapies based on the Company’s immune-educating platform, DPX®

McCarthy Tétrault LLP advised IMV with a team led by Philippe Leclerc that included Mireille Trottier, Annie Poirier-Simard (Securities), Marie-Soleil Landry and Geneviève Favreau (Tax).